Flushing. Menopausal and female climacteric states
Conditions
Interventions
Intervention 1: Intervention group: Gabapentin Capsule 300 mg- TDS-during 3 months. Intervention 2: Control group: Placebo as capsules, three times a day for 3 months.
Treatment - Drugs
Placebo
Intervention group: Gabapentin Capsule 300 mg- TDS-during 3 months
Control group: Placebo as capsules, three times a day for 3 months
Sponsors
Jundishapour Medical University
Eligibility
Sex/Gender
Female
Age
40 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria : Elapsing one year of last menstrual phase(LMP), Follicle-stimulating hormone (FSH) more than 40IU/L and not using any drugs that affect on hot flush symptoms. Exclusion criteria : happening Gabapentin side effects, noncompliance and coexistence of systemic disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flushing severity. Timepoint: Before intervention, 1 month after intervention, 2months later and 3 months later after intervention. Method of measurement: Visual Analoge Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Flushing duration. Timepoint: Before intervention, 1 month after intervention, 2months later and 3 months later after intervention. Method of measurement: Patients notation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Solmaz Natanj
Ahvaz Jundishapour Medical University
Outcome results
None listed